Oncogene mutations in cutaneous melanomas of different origin
Abstract
Melanoma is the most lethal malignancy of skin, which is characterized with clinical and molecular heterogeneity. The main role in melanoma carcinogenesis belongs to mitogen-activated protein kinase MAPK signaling pathway, which is hyperactivated mostly due to BRAF and NRAS mutations. Aim of the study was the analysis of oncogene mutations in melanomas of different origin. BRAF mutations were found in 60,4%, NRAS in 15,6% and KIT in 1% of tumor samples, most of which were regional metastases. The frequency of BRAF mutations were higher in tumors developed on trunk and extremities (69%), then in melanomas located on face and head with chronic UV exposure (44%). NRAS mutations were more common- in melanomas on face (33%) and low extremities (28%), then in tumors on trunk. BRAF mutations were found in 70% of patients younger 40 years while the median age for the group of patients with NRAS mutations was 62 years. There were no differences in frequency of oncogene mutations observed in pigmented and amelanotic tumors, as well as superficial spreading and nodal melanоmas. Cutaneous melanomas have prevalently epithelioid phenotype and BRAF и NRAS mutation frequencies in epithelioid melanomas were higher than in spindle cell and nevoid ones. Thus BRAF и NRAS mutations are associated with location of primary melanoma, histologic type of tumor and age of patients.
About the Authors
I. V. TsyganovaRussian Federation
Moscow
O. A. Anurova
Russian Federation
Moscow
N. N. Mazurenko
Russian Federation
Moscow
References
1. Мазуренко Н.Н. Генетические особенности и маркеры меланомы кожи. Молекулярный канцерогенез. Под ред. КрасильниковаМ.А.,ЗборовскойИ.Б.М., 2016, с. 253-273.
2. Rajkumar S., Watson I.R. Molecular characterization of cutaneous melanoma: creating a framework for targeted and immune therapies. British J. Cancer. 2016, v. 115, No. 2, p. 145-155.
3. Bello D.M.,Ariyan C.E., Carvajal R.D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013, v. 20, No. 4, p. 261-281.
4. Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Molecular Oncology. 2008, v. 1, No. 4, p. 395-405.
5. Ellenrhorst J., Greene V.R., Ekmekcioglu S. et al. Clinical correlations of NRAS and BRAF mutations in primary human melanoma. Clinical Cancer Research. 2011, v. 17, No. 2, p. 229-235.
6. Fedorenko I.V., Gibney G.T.,Keiran S.M. NRAS mutant melanoma: biological behavior and future strategiesfortherapeutic management. Oncogene. 2013, v. 32, No. 25, p. 3009-3018.
7. Beadling C., Jacobson-Dunlop E., Hodi F.S. et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008, v. 14, No. 21, p. 6821-6828.
8. Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases. 2011, v. 2, No. 5, p. 289-292.
9. Grimaldi A.M., Simeone E., Festino L. et al. Novel mechanisms and therapeutic approachesin melanoma: targeting the MAPK pathway. Discovery Medicine. 2015, v. 19, No. 107, p. 455-461.
10. Larkin J.,AsciertoP.A., DrenoB. et al. Combined vemurafenib and cobimetinib in BRAF – mutated melanoma. N. Engl. J. Med. 2014, v. 371, No. 20, p. 1867-1876.
11. Мазуренко Н.Н., Цыганова И.В., Лушникова А.А. и соавт. Спектр мутаций онкогенов различается в субтипах меланомы кожи. Молекулярная биология. 2015, т. 59, № 6, с.1022-1029.
12. Vredeveld L.C., Possik P.A., Smit M.A. et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012, v. 26, No. 10, p. 1055-1069.
13. Bowyer S.E., Rao A.D., Lyle M. et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res. 2014, v. 24, No. 5, p. 504-508.
Review
For citations:
Tsyganova I.V., Anurova O.A., Mazurenko N.N. Oncogene mutations in cutaneous melanomas of different origin. Bone and soft tissue sarcomas, tumors of the skin. 2016;(3):3-6. (In Russ.)